17 Aug 2023 , 11:54 AM
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the USFDA for generic Icatibant injection used in treating hereditary angioedema. The approved injection is of strength 30 mg/3 mL (10 mg/mL) and comes in a single-dose pre-filled syringe.
The product is considered bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals’ reference listed drug FIRAZYR. Aurobindo Pharma announced the product’s launch in September 2023. The approved product’s market size is estimated to be approximately USD 137 million based on IQVIA data for the 12 months ending June 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.